The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design
Open accessAbstract
Pyridine-based ring systems are one of the most extensively used heterocycles in the field of drug design, primarily due to their profound effect on pharmacological activity, which has led to the discovery of numerous broad-spectrum therapeutic agents. In the US FDA database, there are 95 approved pharmaceuticals that stem from pyridine or dihydropyridine, including isoniazid and ethionamide (tuberculosis), delavirdine (HIV/AIDS), abiraterone acetate (prostate cancer), tacrine (Alzheimer's), ciclopirox (ringworm and athlete's foot), crizotinib (cancer), nifedipine (Raynaud's syndrome and premature birth), piroxicam (NSAID for arthritis), nilvadipine (hypertension), roflumilast (COPD), pyridostigmine (myasthenia gravis), and many more. Their remarkable therapeutic applications have encouraged researchers to prepare a larger number of biologically active compounds decorated with pyridine or dihydropyridine, expandeing the scope of finding a cure for other ailments. It is thus anticipated that myriad new pharmaceuticals containing the two heterocycles will be available in the forthcoming decade. This review examines the prospects of highly potent bioactive molecules to emphasize the advantages of using pyridine and dihydropyridine in drug design. We cover the most recent developments from 2010 to date, highlighting the ever-expanding role of both scaffolds in the field of medicinal chemistry and drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vitaku, E., Smith, D. T., & Njardarson, J. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501100b · Cited by 6,418
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Myasthenia gravis: subgroup classification and therapeutic strategies
Gilhus, N. E., & Verschuuren, J. J. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00145-3 · Cited by 1,267
Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture
Yang, Y.-X., Lewis, J. D., Epstein, S., & Metz, D. C. (2006) · JAMA · doi:10.1001/jama.296.24.2947 · Cited by 1,214
Cerebral Arterial Spasm – A Controlled Trial of Nimodipine in Patients with Subarachnoid Hemorrhage
Allen, G. S., Ahn, H. S., Preziosi, T. J., Battye, R., Boone, S. C., Chou, S. N., Kelly, D. L., Weir, B. K., Crabbe, R. A., Lavik, P. J., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198303173081103 · Cited by 1,195
Dyslipidemia in type 2 diabetes mellitus
Mooradian, A. D. (2009) · Nature Reviews Endocrinology · doi:10.1038/ncpendmet1066 · Cited by 1,042
NAD+ metabolism in health and disease
Belenky, P., Bogan, K. L., & Brenner, C. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.11.006 · Cited by 981
Inflammation in CNS neurodegenerative diseases
Stephenson, J., Nutma, E., van der Valk, P., & Amor, S. (2018) · Immunology · doi:10.1111/imm.12922 · Cited by 966
Bull, J. A., Mousseau, J. J., Pelletier, G., & Charette, A. B. (2012) · Chemical Reviews · doi:10.1021/cr200251d · Cited by 920
Structure, Function, and Modulation of GABAA Receptors
Sigel, E., & Steinmann, M. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.386664 · Cited by 812
The power to reduce: pyridine nucleotides—small molecules with a multitude of functions
Pollak, N., Dölle, C., & Ziegler, M. (2007) · Biochemical Journal · doi:10.1042/bj20061638 · Cited by 730
Regulation of glucose homeostasis by glucocorticoids
Kuo, T., McQueen, A., Chen, T.-C., & Wang, J.-C. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4939-2895-8_5 · Cited by 723
TTD: Therapeutic Target Database
Chen, X. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.412 · Cited by 716
Wong, D. F., Rosenberg, P. B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H. T., Dannals, R. F., Nandi, A., Brašić, J. R., Ye, W., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069088 · Cited by 684
Expanding the medicinal chemistry synthetic toolbox
Boström, J., Brown, D. G., Young, R. J., & Keserü, G. M. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.116 · Cited by 665
Shaw, A. T., Felip, E., Bauer, T. M., Besse, B., Navarro, A., Postel-Vinay, S., Gainor, J. F., Johnson, M., Dietrich, J., James, L. P., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30680-0 · Cited by 659
Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites
Slater, A. F. G., & Cerami, A. (1992) · Nature · doi:10.1038/355167a0 · Cited by 635
Cohen, E. E. W., Rosen, L. S., Vokes, E. E., Kies, M. S., Forastiere, A. A., Worden, F. P., Kane, M. A., Sherman, E., Kim, S., Bycott, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9566 · Cited by 623
Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0120-7 · Cited by 577
Histamine and H1-antihistamines: Celebrating a century of progress
Simons, F. E. R., & Simons, K. J. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.09.005 · Cited by 541
Burstein, H. J., Sun, Y., Dirix, L. Y., Jiang, Z., Paridaens, R., Tan, A. R., Awada, A., Ranade, A., Jiao, S., Schwartz, G., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8707 · Cited by 522
Cairns, P. (2011) · Cancer Biomarkers · doi:10.3233/cbm-2011-0176 · Cited by 485
Kamanna, V. S., & Kashyap, M. L. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.029 · Cited by 453
The role of the medicinal chemist in drug discovery — then and now
Lombardino, J. G., & Lowe, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1523 · Cited by 452
The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization
Pennington, L. D., & Moustakas, D. T. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01807 · Cited by 408
Walan, A., Bader, J.-P., Classen, M., Lamers, C. B. H. W., Piper, D. W., Rutgersson, K., & Eriksson, S. (1989) · New England Journal of Medicine · doi:10.1056/nejm198901123200201 · Cited by 380
Karlgren, M., Vildhede, A., Norinder, U., Wisniewski, J. R., Kimoto, E., Lai, Y., Haglund, U., & Artursson, P. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300212s · Cited by 369
Hooked on benzodiazepines: GABAA receptor subtypes and addiction
Tan, K. R., Rudolph, U., & Lüscher, C. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.01.004 · Cited by 365
Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib
Deininger, M. W. N., & Druker, B. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.4 · Cited by 365
Old Drugs as New Treatments for Neurodegenerative Diseases
Durães, F., Pinto, M., & Sousa, E. (2018) · Pharmaceuticals · doi:10.3390/ph11020044 · Cited by 343
Mitochondrial dysfunction in neurological disorders: Exploring mitochondrial transplantation
Norat, P., Soldozy, S., Sokolowski, J. D., Gorick, C. M., Kumar, J. S., Chae, Y., Yağmurlu, K., Prada, F., Walker, M., Levitt, M. R., et al. (2020) · npj Regenerative Medicine · doi:10.1038/s41536-020-00107-x · Cited by 342
A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions
Brown, D. G., & Wobst, H. J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01516 · Cited by 320
ethA , inhA , and katG Loci of Ethionamide-Resistant Clinical Mycobacterium tuberculosis Isolates
Morlock, G. P., Metchock, B., Sikes, D., Crawford, J. T., & Cooksey, R. C. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.12.3799-3805.2003 · Cited by 288
Konstantinopoulos, P. A., Barry, W. T., Birrer, M., Westin, S. N., Cadoo, K. A., Shapiro, G. I., Mayer, E. L., O'Cearbhaill, R. E., Coleman, R. L., Kochupurakkal, B., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30905-7 · Cited by 263
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
Wu, J., Zhang, M., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0250-9 · Cited by 254
Molecular mechanisms of chromium in alleviating insulin resistance
Hua, Y., Clark, S., Ren, J., & Sreejayan, N. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.11.001 · Cited by 250
Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs
Fitch, C. D. (2004) · Life Sciences · doi:10.1016/j.lfs.2003.10.003 · Cited by 240
Recent advances in new multicomponent synthesis of structurally diversified 1,4-dihydropyridines
Wan, J.-P., & Liu, Y. (2012) · RSC Advances · doi:10.1039/c2ra21406g · Cited by 234
Self-citationNimodipine for primary degenerative, mixed and vascular dementia
Birks, J., & López-Arrieta, J. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000147 · Cited by 230
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
de Botton, S., Mondesir, J., Willekens, C., & Touat, M. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s70716 · Cited by 220
Huperzine A, A Potential Therapeutic Agent for Treatment of Alzheimer's Disease
Bai, D. L., Tang, X. C., & He, X. C. (2000) · Current Medicinal Chemistry · doi:10.2174/0929867003375281 · Cited by 216
Pharmacodynamic of cyclooxygenase inhibitors in humans
Capone, M. L., Tacconelli, S., Di Francesco, L., Sacchetti, A., Sciulli, M. G., & Patrignani, P. (2007) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2006.05.019 · Cited by 190
Clinical Studies on Chromium Picolinate Supplementation in Diabetes Mellitus—A Review
Broadhurst, C. L., & Domenico, P. (2006) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.8.677 · Cited by 178
Wang, S., Yuan, X., Wang, S., Zhao, W. H., Chen, X., & Yu, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113218 · Cited by 169
Dündar, Y., Dodd, S., Strobl, J., Boland, A., Dickson, R., & Walley, T. (2004) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.594 · Cited by 168
Gepants for the treatment of migraine
Negro, A., & Martelletti, P. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1618830 · Cited by 165
Niewerth, M., Kunze, D., Seibold, M., Schaller, M., Körting, H. C., & Hube, B. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.6.1805-1817.2003 · Cited by 162
Cholinesterase Inhibition for Alzheimer Disease: A Meta-analysis of the Tacrine Trials
Qizilbash, N., Whitehead, A., Higgins, J., Wilcock, G., Schneider, L., Farlow, M., & for the Dementia Trialists' Collaboration (1998) · JAMA · doi:10.1001/jama.280.20.1777 · Cited by 161
Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma
Flaherty, K. T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2505 · Cited by 159
Jackson, K. J., Marks, M. J., Vann, R. E., Chen, X., Gamage, T. F., Warner, J. A., & Damaj, M. I. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.165738 · Cited by 156
Nimodipine Reappraised: An Old Drug With a Future
Carlson, A. P., Hänggi, D., Macdonald, R. L., & Shuttleworth, C. W. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190927113021 · Cited by 156
Merlos, M., Giral, M., Balsa, D., Ferrando, R., Queralt, M., Puigdemont, A., García-Rafanell, J., & FORN, J. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36413-4 · Cited by 146
Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Biologically Active Agents
Chiacchio, M. A., Iannazzo, D., Romeo, R., Giofrè, S. V., & Legnani, L. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180904125400 · Cited by 145
Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones
Roger, C., Roberts, J. A., & Müller, L. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0601-x · Cited by 142
Desai, N. C., Somani, H., Trivedi, A. R., Bhatt, K., Nawale, L., Khedkar, V. M., Jha, P. C., & Sarkar, D. M. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.043 · Cited by 141
Pym, A. S., Domenech, P., Honoré, N., Song, J., Deretic, V., & Cole, S. T. (2001) · Molecular Microbiology · doi:10.1046/j.1365-2958.2001.02427.x · Cited by 138
Betahistine for symptoms of vertigo
Murdin, L. J., Hussain, K., & Schilder, A. G. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010696.pub2 · Cited by 135
Berg, J., Fellier, H., Christoph, T., Grarup, J., & Stimmeder, D. (1999) · Inflammation Research · doi:10.1007/s000110050474 · Cited by 133
FYX-051: A Novel and Potent Hybrid-Type Inhibitor of Xanthine Oxidoreductase
Matsumoto, K., Okamoto, K., Ashizawa, N., & Nishino, T. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.174540 · Cited by 130
Hsu, K. H. K. (1984) · JAMA · doi:10.1001/jama.1984.03340340023018 · Cited by 124
Zinc Pyrithione Inhibits Yeast Growth through Copper Influx and Inactivation of Iron-Sulfur Proteins
Reeder, N. L., Kaplan, J., Xu, J., Youngquist, R. S., Wallace, J., Hu, P., Juhlin, K. D., Schwartz, J. R., Grant, R. A., Fieno, A., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00724-11 · Cited by 116
Pharmacology of the bipyridines: amrinone and milrinone.
Alousi, A. A., & Johnson, D. C. (1986) · PubMed · Cited by 113
Pyridine alkaloids with activity in the central nervous system
Lin, S. X., Curtis, M. A., & Sperry, J. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115820 · Cited by 106
Amlexanox for the Treatment of Recurrent Aphthous Ulcers
Bell, J. B. (2005) · Clinical Drug Investigation · doi:10.2165/00044011-200525090-00001 · Cited by 102
Ceftaroline: A New Cephalosporin with Activity Against Resistant Gram‐Positive Pathogens
Steed, M. E., & Rybak, M. J. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.4.375 · Cited by 98
Khidre, R. E., & Radini, I. A. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-86424-7 · Cited by 94
Vanotti, E., Amici, R., Bargiotti, A., Berthelsen, J., Bosotti, R., Ciavolella, A., Cirla, A., Cristiani, C., D’Alessio, R., Forte, B., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm700956r · Cited by 93
Wang, L., Bharti, Kumar, R., Pavlov, P. F., & Winblad, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112915 · Cited by 92
Wang, J.-G., Kario, K., Lau, T., Wei, Y. Q., Park, C. G., Kim, C. H., Huang, J., Zhang, W., Li, Y., Yan, P. C., et al. (2011) · Hypertension Research · doi:10.1038/hr.2010.259 · Cited by 90
Myasthenia gravis requiring pyridostigmine treatment in a national population cohort
Andersen, J. B., Engeland, A., Owe, J. F., & Gilhus, N. E. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03089.x · Cited by 84
Sodium Channel Molecular Conformations and Antiarrhythmic Drug Affinity
Sheets, M. F., Fozzard, H. A., Lipkind, G. M., & Hanck, D. A. (2010) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2010.03.002 · Cited by 84
Zheng, X., Bauer, P., Baumeister, T., Buckmelter, A. J., Caligiuri, M., Clodfelter, K. H., Han, B., Ho, Y., Kley, N., Lin, J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400186h · Cited by 81
El‐Sayed, W. A., Khalaf, H. S., Mohamed, S. F., et al. (2017) · Russian Journal of General Chemistry · doi:10.1134/s1070363217100279 · Cited by 80
Neuroprotection trials in Parkinson's disease: Systematic review
Hart, R. G., Pearce, L. A., Ravina, B. M., Yaltho, T. C., & Marler, J. R. (2008) · Movement Disorders · doi:10.1002/mds.22432 · Cited by 79
Wittayanarakul, K., Hannongbua, S. V., & Feig, M. (2007) · Journal of Computational Chemistry · doi:10.1002/jcc.20821 · Cited by 78
Imiquimod in basal cell carcinoma: how does it work?
Dummer, R., Urosevic, M., Kempf, W., Hoek, K. S., Hafner, J., & Burg, G. (2003) · British Journal of Dermatology · doi:10.1046/j.0366-077x.2003.05630.x · Cited by 78
Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide
López, B., González, A., Hermida, N., Laviades, C., & Díez, J. (2008) · Kidney International · doi:10.1038/ki.2008.512 · Cited by 74
Xue, J., Diao, J., Cai, G.-B., Deng, L., Zheng, B., Yao, Y., & Song, Y. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300419r · Cited by 71
Alqahtani, A. M., & Bayazeed, A. A. (2020) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2020.11.020 · Cited by 70
Efonidipine Hydrochloride: A Dual Blocker of L‐ and T‐Type Ca2+ Channels
Tanaka, H., & Shigenobu, K. (2002) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2002.tb00084.x · Cited by 69
An update on huperzine A as a treatment for Alzheimer's disease
Little, J. T., Walsh, S. P., & Aisen, P. S. S. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.2.209 · Cited by 68
Inhibition of two different cholinesterases by tacrine
Ahmed, M., da Rocha, J. B. T., Corrêa, M., Mazzanti, C. M. D. A., Zanin, R. F., Morsch, A., Morsch, V. M., & Schetinger, M. R. C. (2006) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.06.002 · Cited by 64
Toal, C. B., Meredith, P. A., & Elliott, H. L. (2012) · Blood Pressure · doi:10.3109/08037051.2012.690615 · Cited by 64
Tacrines for Alzheimer's disease therapy. III. The PyridoTacrines
de los Ríos, C., & Marco-Contelles, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.005 · Cited by 63
Cabotegravir long-acting for HIV-1 prevention
Andrews, C. D., & Heneine, W. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000161 · Cited by 62
SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK)
Asquith, C. R. M., Berger, B., Wan, J., Bennett, J. M., Capuzzi, S. J., Crona, D. J., Drewry, D. H., East, M. P., Elkins, J. M., Fedorov, O., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01213 · Cited by 61
Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents
Kovačková, S., Chang, L., Bekerman, E., Neveu, G., Barouch‐Bentov, R., Chaikuad, A., Heroven, C., Šála, M., Jonghe, S. D., Knapp, S., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501759m · Cited by 58
Zhang, Y., Pavlova, O. A., Chefer, S. I., Hall, A., Kurian, V., Brown, L. L., Kimes, A. S., Mukhin, A. G., & Horti, A. G. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030432v · Cited by 57
Wang, Z., & Vince, R. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.02.007 · Cited by 54
Good pyridine hunting: a biomimic compound, a modifier and a unique pharmacophore in agrochemicals
Владимирович, З. В., Kuzenkov, A. V., & Михайлович, М. А. (2020) · Chemistry of Heterocyclic Compounds · doi:10.1007/s10593-020-02843-w · Cited by 53
Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam
Carty, T. J., Marfat, A., Moore, P. F., et al. (1993) · Inflammation Research · doi:10.1007/bf01998969 · Cited by 52
Pyridine Based Antitumour Compounds Acting at the Colchicine Site
Álvarez, R., Aramburu, L., Puebla, P., Caballero, E., González, M., Vicente, A. A., Medarde, M., & Peláez, R. (2016) · Current Medicinal Chemistry · doi:10.2174/092986732311160420104823 · Cited by 52
Wu, R., Anthes, J. C., Kreutner, W., Harris, A. G., & West, R. E. (2004) · International Archives of Allergy and Immunology · doi:10.1159/000082325 · Cited by 48
Giustini, N., Bernthal, N. M., Bukata, S. V., & Singh, A. S. (2018) · Clinical Sarcoma Research · doi:10.1186/s13569-018-0101-2 · Cited by 48
Ling, Y., Gao, W., Ling, C., Liu, J., Meng, C., Qian, J., Liu, S., Gan, H., Wu, H., Tao, J., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.054 · Cited by 48
Self-citationDring, A. M., Anderson, L. E., Qamar, S., & Stoner, M. A. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.09.018 · Cited by 46
Croom, K. F., & Siddiqui, M. A. A. (2009) · Drugs · doi:10.2165/00003495-200969110-00008 · Cited by 46
Pu, S., Wouters, R., Schor, S., Rozenski, J., Barouch‐Bentov, R., Prugar, L. I., O’Brien, C. M., Brannan, J. M., Dye, J. M., Herdewijn, P. A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00613 · Cited by 44
Pyrido[2,3-d]pyrimidin-7(8H)-ones: Synthesis and Biomedical Applications
Jubete, G., de la Bellacasa, R. P., Estrada‐Tejedor, R., Teixidó, J., & Borrell, J. I. (2019) · Molecules · doi:10.3390/molecules24224161 · Cited by 44
Praveenkumar, E., Gurrapu, N., Kolluri, P. K., Yerragunta, V., Kunduru, B. R., & Subhashini, N. J. P. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103056 · Cited by 43
Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice
Mahoney, C. E., Mochizuki, T., & Scammell, T. E. (2019) · SLEEP · doi:10.1093/sleep/zsz302 · Cited by 42
Roskos, K. V., Bircher, A. J., Maïbach, H. I., & Guy, R. H. (1990) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1990.tb08262.x · Cited by 41
Vormfelde, S. V., Sehrt, D. B., Toliat, M. R., Schirmer, M., Meineke, I., Tzvetkov, M. V., Nürnberg, P., & Brockmöller, J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100131 · Cited by 41
Harvey, J. L., Paine, A. J., Maurel, P., & Wright, M. C. (2000) · PubMed · Cited by 40
Johnson, R., Dludla, P. V., Mabhida, S. E., Benjeddou, M., Louw, J., & February, F. (2019) · Heart Failure Reviews · doi:10.1007/s10741-018-09765-y · Cited by 40
Mohsin, N. U. A., & Ahmad, M. (2020) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902019000418325 · Cited by 39
Liu, X., Liu, H.-F., Xu, S., Song, B.-A., Bhadury, P. S., Zhu, H., Liu, J., & Qi, X.-B. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.05.080 · Cited by 37
Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine
Weber, M., Breier, M. R., Ko, D., Thangaraj, N., Marzan, D., & Swerdlow, N. R. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1419-x · Cited by 37
Vemurafenibfor the treatment of melanoma
Jordan, E., & Kelly, C. M. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.737780 · Cited by 37
Li, B., Yang, Y., Wang, Y. J., Zhang, J., Ding, J., Liu, X., Jin, Y., Lian, B., Ling, Y., & Sun, C. (2021) · iScience · doi:10.1016/j.isci.2021.102302 · Cited by 35
Self-citationMartínez-Gualda, B., Pu, S., Froeyen, M., Herdewijn, P. A., Einav, S., & Jonghe, S. D. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115188 · Cited by 34
Malhotra, H. S., & Plosker, G. L. (2001) · Drugs · doi:10.2165/00003495-200161070-00007 · Cited by 34
Mammoliti, O., Palisse, A., Joannesse, C., Bkassiny, S. E., Allart, B., Jaunet, A., Menet, C. J., Coornaert, B., Sonck, K., Duys, I., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00138 · Cited by 33
Ruciņš, M., Kaldre, D., Pajuste, K., Fernandes, M. A. S., Vicente, J. A. F., Klimavičiusa, L., Jaschenko, E., Kanepe, I., Shestakova, I., Plotniece, M., et al. (2013) · Comptes Rendus Chimie · doi:10.1016/j.crci.2013.07.003 · Cited by 32
Fernandes, M. (2003) · Mitochondrion · doi:10.1016/s1567-7249(03)00060-6 · Cited by 31
Local Glucocorticoid Activation by 11β-Hydroxysteroid Dehydrogenase 1 in Keratinocytes
Terao, M., Itoi, S., Matsumura, S., Yang, L., Murota, H., & Katayama, I. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.01.014 · Cited by 31
A research update on the potential roles of aquaporin 4 in neuroinflammation
Lan, Y., Fang, D., Zhao, J., Ma, T., & Li, S. (2015) · Acta Neurologica Belgica · doi:10.1007/s13760-015-0520-2 · Cited by 30
Clearance of the Antihistamine Doxylamine: Reduced in Elderly Men But Not in Elderly Women
Friedman, H. L., Greenblatt, D. J., Scavone, J. M., Burstein, E. S., Ochs, H. R., Harmatz, J. S., & Shader, R. I. (1989) · Clinical Pharmacokinetics · doi:10.2165/00003088-198916050-00003 · Cited by 30
Huang, H., Degnan, A. P., Balakrishnan, A., Easton, A. E., Gulianello, M., Huang, Y., Matchett, M., Mattson, G. K., Miller, R., Santone, K. S., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.07.065 · Cited by 30
4-Imidazo[2,1-b]thiazole-1,4-DHPs and neuroprotection: preliminary study in hits searching
Leoni, A., Frosini, M., Locatelli, A., Micucci, M., Carotenuto, C., Durante, M., Cosconati, S., & Budriesi, R. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.075 · Cited by 29
Villamizar–Mogotocoro, A., Vargas-Méndez, L. Y., & Kouznetsov, V. V. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105374 · Cited by 29
Phenazopyridine induces and synchronizes neuronal differentiation of embryonic stem cells
Suter, D. M., Preynat‐Seauve, O., Tirefort, D., Féki, A., & Krause, K. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00660.x · Cited by 28
Nonsedating histamine H1-receptor antagonists.
Mann, K. V., Crowe, S. F., & Tietze, K. J. (1989) · PubMed · Cited by 27
Morgan, R. E., Campbell, S. E., Yu, C. Y., Sponseller, C. A., & Muster, H. A. (2012) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318256cdf0 · Cited by 27
Xu, D., Sun, D., Wang, W., Peng, X., Zhan, Z., Ji, Y., Shen, Y., Geng, M., Ai, J., & Duan, W. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113497 · Cited by 27
Krueger, D., Demir, I. E., Ceyhan, G. O., Zeller, F., & Schemann, M. (2018) · Neurogastroenterology & Motility · doi:10.1111/nmo.13311 · Cited by 26
Minami, J., Numabe, A., Andoh, N., Kobayashi, N., Horinaka, S., Ishimitsu, T., & Matsuoka, H. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02056.x · Cited by 25
Marcinkowska, M., Kołaczkowski, M., Kamiński, K., Bucki, A., Pawłowski, M., Siwek, A., Karcz, T. P., Starowicz, G., Słoczyńska, K., Pękala, E., et al. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00432 · Cited by 24
Peters, J., Booth, A., & Peters, R. K. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315582353 · Cited by 20
Anti-Atherosclerotic Potential of Dihydropyridine Calcium Channel Blockers
Ishii, N., Matsumura, T., Shimoda, S., & Araki, E. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.12450 · Cited by 20
Mu, J., Shi, Y., Wu, H., Sun, Z., Yang, M., Liu, X., & Li, B. (2016) · Chemistry Central Journal · doi:10.1186/s13065-016-0196-6 · Cited by 20
Farha, R. K. A., Bustanji, Y. K., Al-Hiari, Y. M., Al‐Qirim, T. M., Shiekha, G. A., & Albashiti, R. (2016) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2016.1222581 · Cited by 20
Wouters, R., Pu, S., Froeyen, M., Lescrinier, E., Einav, S., Herdewijn, P. A., & Jonghe, S. D. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.065 · Cited by 20
Li, J., Kovačková, S., Pu, S., Rozenski, J., Jonghe, S. D., Einav, S., & Herdewijn, P. A. (2015) · MedChemComm · doi:10.1039/c5md00229j · Cited by 19
Synthesis of Highly Potent Anti-Inflammatory Compounds (ROS Inhibitors) from Isonicotinic Acid
Yaqoob, S., Nasim, N., Khanam, R., et al. (2021) · Molecules · doi:10.3390/molecules26051272 · Cited by 18
Castellan, P., Marchioni, M., Castellucci, R., Francesco, P. D., Iantorno, R., Schips, L., & Cindolo, L. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s159824 · Cited by 16
Khan, F., Nasim, N., Wang, Y., Alhazmi, A., Sanam, M., Ul‐Haq, Z., Damayanthi, Y., Ulanova, M., & Jiang, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112863 · Cited by 14
Self-citation1,4-Dihydropyridine Cationic Peptidomimetics with Antibacterial Activity
Lapidot, I., Albeck, A., Gellerman, G., Shatzmiller, S. E., & Grynszpan, F. (2015) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-015-9460-1 · Cited by 13
Bugajski, J., Głód, R., Gądek-Michalska, A., & Bugajski, A. J. (2001) · PubMed · Cited by 11
Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer
Vogiatzi, P., & Claudio, P. P. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.84 · Cited by 10
Yet, L. (2018) · Wiley eBooks · doi:10.1002/9781118686263.ch3 · Cited by 10
Hamza, E. K., Hamdy, N. A., Zarie, E. S., Fakhr, I. M. I., Elwahy, A. H. M., & Awad, H. M. (2020) · ARKIVOC · doi:10.24820/ark.5550190.p011.056 · Cited by 8
Cited by
Pyridine: the scaffolds with significant clinical diversity
De, S., Kumar S K, A., Shah, S. K., Kazi, S., Sarkar, N., Banerjee, S., & Dey, S. (2022) · RSC Advances · doi:10.1039/d2ra01571d · Cited by 349
Šikorová, E., Štěpánková, Š., Frýbová, E., Konečná, K., Korbielová, J., Švarcová, M., Janďourek, O., Pflégr, V., Bősze, S., & Krátký, M. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70188 · Cited by 3
Metadata
- Authors
- Ling, Y., Hao, Z.-Y., Liang, D., Zhang, C.-L., Liu, Y.-F., & Wang, Y.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2021-10
- Volume
- Volume 15
- Pages
- 4289-4338
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W3205136031
- Cited by
- 414
- References
- 143
- FWCI
- 21.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.